This test is most useful if any of these apply to you.
The same ketone result can have very different meanings during a ketogenic diet, a prolonged fast, or an illness with too little insulin. Beta-hydroxybutyrate is an established marker for assessing ketosis and diagnosing and monitoring diabetic ketoacidosis. Its possible use in predicting heart disease, liver outcomes, or longevity is still exploratory.
Your blood level reflects the balance between ketones entering the circulation and tissues using them. It doesn't directly measure how quickly you're burning stored fat. Dietary fat and ketone supplements can also contribute to the result.
Ketone bodies are small fuel molecules produced mainly by the liver from fatty acids. The three are beta-hydroxybutyrate, acetoacetate, and acetone. BHB is usually the most abundant in blood, particularly during ketoacidosis.
Your liver produces ketones for other tissues, including the brain, heart, and muscles. It lacks a key enzyme needed to use them through the usual ketone-burning pathway. Insulin suppresses the release of fatty acids from fat tissue and reduces the liver's ketone production, which helps explain why BHB generally falls after eating and rises during fasting or carbohydrate restriction.
This test measures D-BHB in serum separated from a venous blood draw, using an enzyme-based laboratory assay. D-BHB is the form your liver mainly produces. Results are reported in mmol/L, a unit of concentration. Routine clinical blood testing can also use plasma, but whole-blood meter readings and research measurements require attention to their own methods.
BHB also affects cell signaling. Experiments in cells and animals have found effects on gene activity and inflammatory responses. Those findings help explain scientific interest in ketones, but they don't establish that raising your blood level slows aging or prevents disease.
Diabetic ketoacidosis develops when insufficient insulin allows excessive ketone production and acid accumulation. It can cause severe dehydration and dangerous disturbances in the body's salts. Total potassium stores are often depleted even when the initial blood potassium result is normal or high.
BHB is central to diagnosis, but ketoacidosis also requires evidence that the blood has become too acidic. Blood pH and bicarbonate provide that information. Glucose may be only mildly raised or near normal, particularly with SGLT2 inhibitors, so a reassuring glucose reading cannot exclude the condition.
Urine ketone strips detect acetoacetate and do not detect BHB. They can underestimate ketosis early in DKA. During recovery, BHB converts back into acetoacetate, so urine ketones may remain positive or appear to increase while the condition improves.
Clinical guidance recommends direct blood BHB measurement for diagnosing and monitoring DKA. Both laboratory testing and suitable finger-stick blood meters have a role. A systematic review of small studies in type 1 diabetes found advantages for blood testing in hospital use, recovery time, and costs. Much of that evidence involved capillary testing in children and young people; it doesn't establish that a scheduled venous draw provides the same benefits as timely sick-day testing.
Several large population studies have linked higher circulating ketones with later heart failure and death. The three studies below measured total ketone bodies in plasma using nuclear magnetic resonance, or NMR. NMR identifies chemicals through their magnetic signals. Total ketones include BHB, acetoacetate, and acetone, so these findings concern a related measurement rather than this serum D-BHB result alone.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| About 91,000 UK adults without cardiovascular disease or heart failure, followed for about 13 years | A tenfold difference in total plasma ketones | About 50% higher mortality, 44% higher heart-failure incidence, and 31% higher atherosclerotic cardiovascular disease incidence after adjustment; heart attacks alone were not significantly associated |
| About 6,800 US adults in MESA, followed for about 14 years | A tenfold difference in total plasma ketones | About 80% higher mortality and 70% higher heart-failure incidence after adjustment |
| About 1,750 US adults aged 65 and older in the Cardiovascular Health Study, followed for up to 20 years | The highest fifth of total plasma ketones versus the lowest fifth | About 50% higher mortality; the study also found a heart-failure association using a separate continuous analysis |
These are relative associations across groups, not estimates of what a particular BHB result means for you. Sampling conditions differed between studies, and the studies weren't designed to isolate intentional ketogenic diets. They don't establish that ketones caused the adverse outcomes or that lowering BHB would prevent them.
Studies measuring BHB alone have been less consistent. In about 6,100 Dutch adults followed for roughly eight years, an association with new heart failure weakened after established cardiac risk markers were included. Associations differed between women and men. A separate study of about 3,000 Chinese adults undergoing coronary angiography linked higher serum BHB with more severe coronary artery disease, particularly in women. That selected population cannot establish its value as a screening test in healthy adults.
These findings support studying ketones as markers of metabolic stress. They haven't established a BHB-based cardiovascular risk score, a preventive treatment target, or a benefit from routine screening.
In 478 people with chronic heart failure, higher plasma BHB measured by NMR was associated with higher mortality. Statistical analyses suggested that protein patterns linked to inflammation and tissue breakdown accounted for about three quarters of the association. Such analyses cannot prove that those processes caused the relationship.
In another study of 867 people with advanced heart failure, plasma BHB rose with circulating fatty acids and worse heart pressures. Its association with outcomes disappeared after fatty acids were taken into account. This supports the possibility that BHB reflects the metabolic changes accompanying heart failure, but it doesn't settle whether ketones themselves help or harm the failing heart.
Other findings come from narrowly defined clinical settings. In a retrospective study of surgery for an aortic dissection, major postoperative events occurred in about 32% of the higher-BHB group and 5% of the lower-BHB group. The combined outcome included death, stroke, and other serious complications. Plasma BHB has also been associated with outcomes and disease progression in arrhythmogenic cardiomyopathy, including among initially asymptomatic relatives. Neither study establishes a screening strategy for the general population.
Fasting, dietary carbohydrate restriction, insulin deficiency, and illness can all increase ketones through different combinations of fat release, liver production, and tissue use. In heart failure, increased ketones may also be part of the body's response to altered energy demands. A high concentration alone doesn't identify which process is responsible.
Population associations therefore cannot be applied directly to ketosis deliberately produced by a diet. They establish neither the long-term safety nor the long-term harm of that dietary state.
In 369 people with newly diagnosed type 2 diabetes, higher serum BHB was associated with worse starting blood glucose and measures of lower insulin secretion. Those with higher BHB also had greater HbA1c improvement after six months of treatment. This observational finding doesn't show that higher ketones caused the improvement.
In 453 Korean adults with impaired fasting glucose followed for nearly 11 years, serum BHB did not reliably predict progression to diabetes after adjustment. BHB therefore cannot replace glucose or HbA1c for assessing diabetes risk, and neither a fasting insulin result nor HbA1c alone can establish why your ketones are raised.
One study found plasma BHB about 20% lower in people with cirrhosis than in matched controls. Within the cirrhosis group, the highest third had an estimated death rate about eight times that of the middle third. The estimate was imprecise: the study included 125 people and 27 deaths. The apparent increase at the lowest levels was not statistically reliable.
These measurements used plasma NMR. The findings suggest altered ketone metabolism in cirrhosis, but they don't establish that a low BHB result means your liver cannot produce enough ketones, or that either end of the distribution is a treatment target.
In about 262,000 UK adults, plasma BHB measured by NMR did not independently predict Alzheimer's disease after adjustment. The study explored differences by genetic risk, but it doesn't support using this test to estimate your dementia risk.
BHB changes substantially with recent food intake and energy use. A small study that sampled 12 healthy adults on consecutive mornings found considerable variation within the same person, even under fasting conditions. A single result may not represent your usual level.
Evidence-backed interventions that affect your Beta-Hydroxybutyrate level
Beta-Hydroxybutyrate is best interpreted alongside these tests.